Bend Research & Xcelience Ink Drug Development Deal

The collaboration will combine Bend’s formulation/processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development expertise.

US-based drug manufacturer Bend Research and contract research organization Xcelience have announced their collaboration to provide oral solid solubilization formulation solutions and clinical supply manufacture in combined programs to clients.

The collaboration will provide streamlined solutions to clients with challenging drug development candidates by combining Bend’s formulation/processing expertise for delivering poorly soluble compounds with Xcelience’s early-phase development expertise.

"This collaboration reduces project timelines and transfer risk more than would be possible if the two steps occurred sequentially,” said Xcelience chief executive officer and president Derek Hennecke. “It's a perfect example of what can happen when two organizations combine to push the